E-drug: accesss to HIV-related drugs in developing countries
---------------------------------------------
The EDM Programme of the World Health Organization with UNAIDS
have asked us to identify problems that have arisen in public sector
projects which aim at increasing accesss to HIV-related drugs in
developing countries. Could E-drug readers working in essential drugs
programmes contribute to this project by filling in below questionnaire.
There are only 9 questions. We would be grateful for any information
you can provide (even if you can only answer a few of the questions).
We will keep e-drug readers informed on the results of this project.
Anita Hardon
Medical Anthropology Unit
Department of Anthropology
Faculty of Social and Behavorial Sciences
University of Amsterdam
Oudezijds Achterburgwal 185
1012 DK Amsterdam
fax: 31 20 5253010
tel: 31 20 5252670
e-mail: hardon@pscw.uva.nl
--------------------------------------
Questionnaire on access to HIV-related medicines in developing
countries:
Respondent:
Professional position:
Address:
Country:
1. Has the essential drugs list in your country been adapted in
response to medicine needs of people living with HIV/AIDS ? If yes,
do you know which criteria were used to decide if HIV-related
medicines should be included on the list or not.
2. Are the following key HIV-related medicines listed on the essential
drugs list in your country? (Fill in yes/no)
gentamicin injection (antibacterial)
sulfamethoxazole+trimethoprim/co-trimoxazole tablets (antibacterial)
isoniazid tablets (antituberculous)
nystatin pessaries (antifungal)
ketoconazole tablets (antifungal)
fluconazole tablets/capsules (antifungal)
aciclovir tablets, (anti-herpesvirus)
pyrimethamine tablets(antitoxoplasmosis)
sulfadiazine tablets (antibacterial antitoxoplasmosis)
calcium folinate tablets (cytotoxic)
calamine lotion with sulphur 2 (anti-inflammatory and antipruritic)
loperamide tablets(anti-diarrhea)
code�ne tablets (opiod analgesic)
morphine sulfate injection/ampoules(opioid analgesic)
vinblastine powder for injection, (sulfate) in vial or vincristine powder
for injection, (sulfate) in vial (anti-cancer, Kaposi sarcoma)
zidovudine capsules/AZT (anti-retroviral)
didanosine (ddI)(anti-retroviral)
stavudine (d4T)(anti-retroviral)
lamivudine (3TC)(anti-retroviral)
nevirapine (anti-retroviral)
protease inhibitor (indinavir or nelfinavir or ritonavir or saquinavir)
female condoms
male condoms
3. Are the following key HIV-related medicines available in first-line
public health facilities (please fill in generally available, limited
availability or not available).
gentamicin injection (antibacterial)
sulfamethoxazole+trimethoprim/co-trimoxazole tablets (antibacterial)
isoniazid tablets (antituberculous)
nystatin pessaries (antifungal)
ketoconazole tablets (antifungal)
fluconazole tablets/capsules (antifungal)
aciclovir tablets, (anti-herpesvirus)
pyrimethamine tablets(antitoxoplasmosis)
sulfadiazine tablets (antibacterial antitoxoplasmosis)
calcium folinate tablets (cytotoxic)
calamine lotion with sulphur 2 (anti-inflammatory and antipruritic)
loperamide tablets(anti-diarrhea)
code�ne tablets (opiod analgesic)
morphine sulfate injection/ampoules(opioid analgesic)
vinblastine powder for injection, (sulfate) in vial or vincristine powder
for injection, (sulfate) in vial (anti-cancer, Kaposi sarcoma)
zidovudine capsules/AZT (anti-retroviral)
didanosine (ddI)(anti-retroviral)
stavudine (d4T)(anti-retroviral)
lamivudine (3TC)(anti-retroviral)
nevirapine (anti-retroviral)
protease inhibitor (indinavir or nelfinavir or ritonavir or saquinavir)
female condoms
male condoms
4. Are data available in your country on the incidence/prevalence of
HIV-related opportunistic infections? If yes, (a) what are the most
common opportunistic infections? And, (b) are the data used to
quantify HIV-related medicine needs for the essential drugs
programme?
5. Are anti-retrovirals made available in public health care facilities? If
yes, for which purposes (fill in yes/no)
a. Prevention of mother to child transmission?
b. Post-exposure prophylaxis for health workers?
c. Therapy for people living with HIV/AIDS?
6. Is there a system for voluntary HIV testing and counselling in the
public health services? If yes, does it function well?
7. Have health workers in first-line health centres/clinics in your
country been trained in (fill in yes/no)
a. the diagnosis and treatment of common HIV-related opportunistic
infections?
b. the diagnosis and treatment of sexually transmitted diseases?
c. the prevention of mother to child transmission using antiretrovirals?
d. the rational prescription and use of antiretroviral therapy to treat
people living with HIV/AIDS
8. Do guidelines exist in your country on (fill in yes/no):
a. the diagnosis and treatment of common HIV-related opportunistic
infections?
b. the diagnosis and treatment of sexually transmitted diseases?
c. the prevention of mother to child transmission using antiretrovirals?
d. the rational prescription and use of antiretroviral therapy to treat
people living with HIV/AIDS?
9. Can the public health care system in your view cope with the
medicine needs of people living with HIV and AIDS? What are
constraints?
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.